Legal & General Group Plc Grows Stake in BioCryst Pharmaceuticals, Inc. (BCRX)
Legal & General Group Plc raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,346 shares of the biotechnology company’s stock after purchasing an additional 860 shares during the quarter. Legal & General Group Plc’s holdings in BioCryst Pharmaceuticals were worth $102,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in BCRX. Vanguard Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 49.1% in the 1st quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock worth $42,098,000 after purchasing an additional 1,651,292 shares during the period. FMR LLC raised its holdings in shares of BioCryst Pharmaceuticals by 97.5% in the 1st quarter. FMR LLC now owns 1,456,885 shares of the biotechnology company’s stock worth $12,238,000 after purchasing an additional 719,162 shares during the period. Geode Capital Management LLC raised its holdings in shares of BioCryst Pharmaceuticals by 49.5% in the 1st quarter. Geode Capital Management LLC now owns 773,115 shares of the biotechnology company’s stock worth $6,493,000 after purchasing an additional 255,975 shares during the period. Wellington Management Group LLP purchased a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth about $1,700,000. Finally, State Street Corp raised its holdings in shares of BioCryst Pharmaceuticals by 8.6% in the 1st quarter. State Street Corp now owns 2,272,104 shares of the biotechnology company’s stock worth $19,083,000 after purchasing an additional 179,216 shares during the period. Institutional investors own 70.21% of the company’s stock.
A number of equities analysts have recently commented on the company. Noble Financial restated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. HC Wainwright restated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. ValuEngine downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. BidaskClub upgraded BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 5th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.78.
In related news, Director Fred E. Cohen sold 54,250 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $5.42, for a total transaction of $294,035.00. Following the completion of the transaction, the director now owns 173,660 shares of the company’s stock, valued at approximately $941,237.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.80% of the stock is owned by insiders.
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ BCRX) opened at 5.10 on Friday. BioCryst Pharmaceuticals, Inc. has a one year low of $3.75 and a one year high of $9.25. The company’s 50 day moving average price is $5.25 and its 200 day moving average price is $5.56. The stock’s market capitalization is $410.18 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The company had revenue of $3.10 million during the quarter, compared to analyst estimates of $5.79 million. During the same period in the prior year, the firm earned ($0.22) EPS. BioCryst Pharmaceuticals’s quarterly revenue was down 35.4% on a year-over-year basis. On average, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post ($0.75) earnings per share for the current year.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.